Latest News

Flexion Therapeutics (NASDAQ:FLXN) Posts Earnings Results, Beats Estimates By $0.01 EPS

Flexion Therapeutics (NASDAQ:FLXN) issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($1.00) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.01) by $0.01, Fidelity Earnings reports. The business had revenue of $21.79 million for the quarter, compared to analyst estimates of $18.85 million. Flexion Therapeutics had a negative return on equity of 271.22% and a negative net margin of 266.51%.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Shares of Flexion Therapeutics stock traded up $0.11 during midday trading on Friday, hitting $16.09. 474,900 shares of the company were exchanged, compared to its average volume of 624,557. The company has a debt-to-equity ratio of 27.76, a current ratio of 5.96 and a quick ratio of 5.57. The firm has a market cap of $610.03 million, a P/E ratio of -3.58 and a beta of 1.38. The firm has a 50 day simple moving average of $14.98 and a 200-day simple moving average of $12.53. Flexion Therapeutics has a 52 week low of $8.76 and a 52 week high of $17.82.

Several analysts recently weighed in on FLXN shares. Zacks Investment Research downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. BidaskClub downgraded Flexion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Northland Securities set a $20.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 10th. Finally, ValuEngine downgraded Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $23.57.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Recommended Story: Limitations of analyzing profit margin

Earnings History for Flexion Therapeutics (NASDAQ:FLXN)

Leave a Reply

Your email address will not be published. Required fields are marked *